Each filer's latest filing for 63008G203 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Murchinson Ltd.
13D/A
|
10.1% |
10/29/2026
Event 10/22/2026
|
||
| Murchinson Ltd. | 10.1% | |||
| Nomis Bay Ltd. | 3.0% | |||
| BPY Ltd. | 2.0% | |||
| EOM Management Ltd. | 5.1% | |||
| James Keyes | 5.1% | |||
| Jason Jagessar | 5.1% | |||
| Chaja Carlebach | 5.1% | |||
| Clarendon Hugh Masters | 5.1% | |||
| Marc J. Bistricer | 10.1% | |||
|
Tang Capital Management LLC
13G
|
9.1% |
8/21/2026
Event 8/19/2026
|
||
| Tang Capital Management, LLC | 9.1% | |||
| Kevin Tang | 9.1% | |||
| Tang Capital Partners, LP | 2.1% | |||
| Tang Capital Partners International, LP | 2.8% | |||
| Tang Capital Partners III, Inc | 2.1% | |||
| Tang Capital Partners IV, Inc | 2.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Anson Funds Management LP
13D/A
|
4.2% |
7/14/2025
Event 7/11/2025
|
||
| Anson Funds Management LP | 4.2% | |||
| Anson Management GP LLC | 4.2% | |||
| Tony Moore | 4.2% | |||
| Anson Advisors Inc. | 4.2% | |||
| Amin Nathoo | 4.2% | |||
| Moez Kassam | 4.2% | |||
| Oramed Pharmaceuticals Inc. 13D/A | 3.3% |
7/22/2026
Event 7/20/2026
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 109 | 86.8 M | $136M |
| 2026 Q2 | 108 | 67.2 M | $97.4M |
| 2026 Q1 | 110 | 59.1 M | $100M |
| 2025 Q4 | 116 | 70.0 M | $108M |
| 2025 Q3 | 117 | 71.4 M | $112M |
| 2025 Q2 | 131 | 77.2 M | $125M |
| 2025 Q1 | 144 | 74.3 M | $118M |
| 2024 Q4 | 148 | 76.0 M | $189M |
| 2024 Q3 | 141 | 70.7 M | $173M |
| 2024 Q2 | 134 | 73.2 M | $161M |
| 2024 Q1 | 132 | 75.0 M | $209M |
| 2023 Q4 | 141 | 72.2 M | $173M |
| 2023 Q3 | 140 | 69.7 M | $189M |
| 2023 Q2 | 140 | 74.6 M | $216M |
| 2023 Q1 | 145 | 75.1 M | $216M |
| 2022 Q4 | 149 | 64.7 M | $1.07B |
| 2022 Q3 | 152 | 60.6 M | $145M |
| 2022 Q2 | 156 | 64.9 M | $201M |
| 2022 Q1 | 158 | 57.2 M | $204M |
| 2021 Q4 | 160 | 51.4 M | $197M |
| 2021 Q3 | 150 | 47.9 M | $271M |
| 2021 Q2 | 162 | 52.3 M | $431M |
| 2021 Q1 | 144 | 43.1 M | $370M |
| 2020 Q4 | 102 | 23.2 M | $211M |
| 2020 Q3 | 36 | 1.47 M | $4.21M |
| 2020 Q2 | 31 | 1.28 M | $2.81M |
| 2020 Q1 | 12 | 365 k | $349k |
| 2019 Q4 | 10 | 94.4 k | $243k |
| 2019 Q3 | 2 | 743 k | $305k |
| 2019 Q2 | 1 | 800 | $7.00k |
| 2019 Q1 | 1 | 800 | $7.00k |